TIDMIUG
RNS Number : 8201W
Intelligent Ultrasound Group PLC
20 April 2023
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the retained EU law version of the Market Abuse Regulation (EU) No.
596/2014 (the "UK MAR") which is part of UK law by virtue of the
European Union (Withdrawal) Act 2018. Upon the publication of this
announcement via the Regulatory Information Service, this inside
information is considered to be in the public domain
Intelligent Ultrasound Group plc
("Intelligent Ultrasound" or the "Group" or the "Company")
Audited Results for the Year Ended 31 December 2022
Intelligent Ultrasound Group plc (AIM: IUG), the ultrasound
artificial intelligence (AI) software and simulation company,
announces its audited results for the year ended 31 December 2022,
showing another year of significant progress.
Financial highlights:
-- Group revenue grew by 33% to GBP10.1m (2021: GBP7.6m)
-- Clinical AI-related revenue grew by over 200% to GBP0.7m (2021: GBP0.2m)
-- Simulation related revenue grew by 28% to GBP9.4m (2021: GBP7.4m)
-- Loss after tax reduced to GBP3.0m (2021: GBP3.6m)
-- Year-end cash at GBP7.2m (31 December 2021: GBP5.0m) after a
GBP4.8m placing (net of fees) and no debt (excluding IFRS 16 lease
liabilities)
Operational highlights:
-- GE HealthCare launched the SonoLyst technology, that utilises
our ScanNav Assist AI software, on the Voluson Expert 22 ultrasound
machine in July
-- ScanNav Anatomy Peripheral Nerve Block (PNB), our second
AI-driven product, received FDA De Novo clearance for sale in the
US in October
-- NeedleTrainer 2.0, our third AI-related product, to teach
ultrasound-guided needling to medical professionals, was launched
in September and now incorporates the GE HealthCare Vscan Air
ultrasound device
-- We began a charitable partnership with the World Federation
for Ultrasound in Medicine and Biology ("WFUMB") to support their
mission to bring sustainable ultrasound training programmes to the
underserved areas of the world
Commenting on the results, Riccardo Pigliucci, Chairman of
Intelligent Ultrasound said: "This has been another year of
significant progress for the Group. We have increased Group revenue
by over 30%, achieved the important milestone of FDA clearance for
our second AI-driven product and continue to build an excellent
partnership with the world's leading ultrasound company - GE
HealthCare. With a positive start in Q1 23, a growing range of AI
and simulation related products, an established operational base,
and year end cash of GBP7.2m, we expect to continue this growth
during 2023 and remain excited about the long-term potential of our
unique 'Classroom to Clinic' model."
For further information, please contact:
Intelligent Ultrasound Group www. intelligentultrasound.com
plc
Stuart Gall, CEO Tel: +44 (0)29 2075 6534
Helen Jones, CFO
Tel: +44 (0)20 7397 8900
Cenkos Securities - Nominated
Advisor and
Broker
Giles Balleny / Max Gould
(Corporate Finance)
Dale Bellis / Julian Morse
(Sales)
Tel: +44 (0)20 7933 8780 or intelligentultrasound@walbrookpr.com
Walbrook PR
Anna Dunphy / Paul McManus Mob: +44 (0)7876 741 001 / Mob: +44
(0)7980 541 893
ABOUT INTELLIGENT ULTRASOUND GROUP
Intelligent Ultrasound (AIM: IUG) is one of the world's leading
'classroom to clinic' ultrasound companies, specialising in
real-time hi-fidelity virtual reality simulation for the ultrasound
training market ('classroom') and artificial intelligence-based
clinical image analysis software tools for the diagnostic medical
ultrasound market ('clinic'). Based in Cardiff in the UK and
Atlanta in the USA, the Group has two revenue streams:
Simulation
Real-time hi-fidelity ultrasound education and training through
simulation. Our main products are the ScanTrainer obstetrics and
gynaecology training simulator, the HeartWorks echocardiography
training simulator, the BodyWorks Eve Point of Care and Emergency
Medicine training simulator with Covid-19 module and the new
BabyWorks Neonate and Paediatric training simulator. To date c.
1500 simulators have been sold to over 750 medical institutions
around the world.
Clinical AI software
Deep learning-based algorithms to make ultrasound machines
smarter and more accessible using our proprietary ScanNav
ultrasound image analysis technology. Current products on the
market utilising this technology are GE HealthCare's SonoLyst
software that is incorporated in their Voluson Expert 22 and SWIFT
ultrasound machines; ScanNav Anatomy PNB that simplifies ultrasound
image interpretation by providing the user with real-time AI-based
anatomy highlighting for a range of ultrasound guided regional
anaesthesia procedures; and NeedleTrainer that teaches real-time
ultrasound-guided needling and incorporates ScanNav Anatomy
PNB.
www.intelligentultrasound.com
CHAIRMAN'S STATEMENT
This has been another year of significant progress across the
business. We have increased Group revenue by 33% to GBP10.1m (2021:
GBP7.6m), achieved FDA De Novo clearance for our second AI-driven
clinical product in the real-time ultrasound image analysis market
and, with the launch of SonoLyst on the Voluson Expert 22
ultrasound machine, are building an excellent partnership with GE
HealthCare - the world's leading ultrasound company.
Clinical AI:
-- Revenue grew by over 200% to GBP0.7m in 2022 (2021: GBP0.2m)
-- GE HealthCare launched the SonoLyst technology on the Voluson
Expert 22 ultrasound machine in July. SonoLyst utilises our ScanNav
Assist AI software technology and is the world's first fully
integrated ultrasound AI tool that recognises the 21 views
recommended by the International Society of Ultrasound in
Obstetrics and Gynaecology (ISUOG) mid-trimester practice
guidelines for fetal imaging
-- ScanNav Anatomy Peripheral Nerve Block (PNB), our second AI
driven product, received FDA De Novo clearance in October for sale
in the US
-- NeedleTrainer 2.0, our third AI-related product, to teach
ultrasound-guided needling to medical professionals, was launched
in September and now incorporates the GE HealthCare Vscan Air
handheld ultrasound device
Simulation:
-- Revenue grew by 28% to GBP9.4m in 2022 (2021: GBP7.4m),
primarily driven by UK direct sales that grew by 96% to GBP4.9m
(2021: GBP2.5m)
-- Direct sales revenue in the North American market was broadly
flat due to the tighter than expected market in the second half of
the year being positively offset by currency swings
-- Sales in Europe and Asia, that are made through our reseller
network, declined to GBP1.7m (2021: GBP2.1m), largely due to the
restrictions of Covid-19 on the Chinese market
Group:
-- Loss after tax reduced to GBP3.0m (2021: loss of GBP3.6m)
-- Cash at bank at 31 December 2022 was GBP7.2m (2021: GBP5.0m)
after an oversubscribed placing in November raised GBP4.8m (net of
fees) from new and existing shareholders
-- Agreed a charitable partnership with the World Federation for
Ultrasound in Medicine and Biology ("WFUMB") to help support their
mission to bring sustainable ultrasound training programmes to the
underserved areas of the world
Strategy
We continue to progress our unique 'Classroom to Clinic'
ultrasound strategy based on:
-- Growing the Group's 'Classroom' related revenues through
increased sales from our existing simulator platforms sold through
our direct sales operations in the UK and US, and our global
reseller channels; and the continued expansion of our range of
ultrasound training simulators into new medical market segments
-- Building our 'Clinic' related AI revenues through increased
revenue from royalty sales from GE HealthCare, who incorporate our
ScanNav AI technology in their Voluson SWIFT and Expert 22
ultrasound systems; increased sales of our proprietary stand-alone
AI-driven ScanNav Anatomy and NeedleTrainer systems, sold through
our direct sales and reseller operations; and future new
proprietary stand-alone AI-driven products aimed at new medical
markets
We believe that our 'Classroom to Clinic' approach allows us to
capture future clinical customers early in their medical careers,
aiding brand recognition and product credibility as the ex-trainees
progress their careers and increase their purchasing influence.
In the NeedleTrainer/Anatomy PNB example, there is a direct path
from first learning basic skills with simulation in the classroom
then, under supervision, learning on patients in clinical practice
with the AI support tools and finally providing real-time AI-based
support to practitioners' independent clinical practice.
We believe this unique 'classroom to clinic' approach to
ultrasound will enable the Group to continue to grow in 2023 and
reach profitability by the end of 2024.
People
Our people continue to have a pivotal role in our success and I
would like to thank all our staff, in both the UK and the US, for
working so hard and performing so well during a record year.
Without their invaluable contribution we would not have achieved
all the key milestones we set out to shareholders at the beginning
of the year.
Shareholders
We are privileged to have such a supportive group of
shareholders. During the second half of the year, we raised GBP5.2m
(GBP4.8m net of fees) from new and existing shareholders and I
would like to thank them for their continued support. It was
pleasure to meet a number of our shareholders during our two
technology open days that were held in London, and we will look to
expand these events in 2023. As always, we maintain an open-door
policy at our head office in Cardiff and welcome any visitors who
wish to experience our cutting edge 'classroom to clinic'
technology.
Board and governance
The Board aims to maintain the highest standards of corporate
governance and is continuing to appoint new diverse, experienced
and independent non-executive Directors, as some of our longest
serving Directors retire.
-- In August 2022 we were delighted to welcome Dr Christian
Guttmann as a Non-executive Director to the Board. Christian is a
recognised leader in shaping the global agenda on AI regulation and
standards, as well as having outstanding AI research, development
and commercialisation experience. He has edited and authored seven
books, over 50 publications and has three patents in the field of
AI
-- At the 2022 AGM Prof Nazar Amso, one of the original founders
of the company and David Baynes, representing the largest
pre-listing investor, did not seek re-election and retired from the
Board
-- On 31 December 2022 Andrew Barker, who joined the Board after
the acquisition in 2017 of Intelligent Ultrasound Ltd, retired.
I would like to thank all three retiring Directors for their
outstanding contribution to the business. They have all worked
tirelessly to support the Group and their input to the Board will
be missed.
ESG
This is our second full year of ESG reporting and we have
continued to make significant progress in all aspects of our
reporting. For the first time we have provided a full calculation
of our Scope 3 emissions and are delighted to be working with the
World Federation for Ultrasound in Medicine and Biology ("WFUMB")
in their mission to bring sustainable ultrasound training
programmes to the underserved areas of the world. We continue to
instigate new initiatives to promote better employee and local
engagement and believe we continue to have a positive impact
locally, nationally and globally. We look forward to continuing our
ESG journey.
Outlook
This has been another year of significant progress for the
Group. We have increased Group revenue by over 30%, achieved the
important milestone of FDA clearance for our second AI-driven
product and continue to build an excellent partnership with the
world's leading ultrasound company - GE HealthCare. With a positive
start in Q1 2023, a growing range of both AI and simulation related
products, an established operational base, and year end cash of
GBP7.2m, we expect to continue this growth during 2023 and remain
excited about the long-term potential of our unique 'Classroom to
Clinic' model.
Riccardo Pigliucci
Non-executive Chairman
CEO REVIEW
Our vision is to make clinical diagnostic ultrasound easier to
learn and simpler to use by providing clinicians around the world
with real-time support from the classroom to the clinic. With the
global market for artificial intelligence (AI) based ultrasound
software expected to be $1.3bn by 2028, AI remains a key element of
our approach, as we expand both our simulation and clinical sales
operations.
Based in Cardiff (UK), Alpharetta (US) and with representation
in Beijing (China), the report below details the progress made in
2022 and the key challenges faced during the year.
SIMULATION (Classroom)
Training medical professionals in the specialist skills required
to competently scan a patient using the diagnostic capabilities of
ultrasound remains a key foundation stone of our business. We
design, develop and sell some of the world's leading hi-fidelity
ultrasound training systems and consider ourselves one of the
world's leading companies in this growing market.
In 2022 simulation revenue increased by 28% to GBP9.4m (2021:
GBP7.4m) and we now have four ultrasound simulation-only platform
technologies focussed on the following markets:
-- ScanTrainer - obstetrics and gynaecology (OBGYN)
-- HeartWorks - echocardiography and anaesthesiology (ECHO)
-- BodyWorks - emergency medicine, critical care and point-of-care (PoCUS)
-- BabyWorks (officially launched in the US in January 2022) - neonate and paediatrics
During 2022, the majority of the simulation revenues came from
our ScanTrainer, HeartWorks and BodyWorks platforms. In 2023 it is
anticipated that BabyWorks will materially contribute to the
simulation revenue stream, as we open up this new market.
The four ultrasound training platforms are, in the main, high
value, capital equipment sold to the global medical institution
market, through our direct sales forces in the US and UK and a
network of 23 resellers covering 33 countries in the rest of the
world. To date we have sold c. 1,500 simulators into over 750
medical institutions around the world.
Research & Development
During the year, the simulation R&D team focussed on four
developments:
Launch of BodyWorks 4.0
In October we launched the latest version of our BodyWorks
ultra-realistic female patient simulator for PoCUS scenario
training with updated and enhanced images and an expanded range of
modules to teach novice users how to develop ultrasound skills and
competence in a non-clinical environment.
The first set of cardiac pathologies for the BabyWorks
simulator
In November we launched the first suite of cardiac pathologies
for the new BabyWorks augmented reality simulator which aims to aid
medical trainees in the diagnosis and understanding of three
important cardiac pathologies in the neonatal and paediatric
intensive care settings. Further suites of pathologies are expected
to be developed and launched during 2023.
Range of e-learning modules
With medical professionals needing to continually build their
learning and confidence, during the year we collaborated with a
number of experts in their field to create five distance learning
courses that provide high quality continuous education and
improvement within ultrasound and healthcare. Sold as an integrated
package or as an individual license, we expect to continue to roll
out these modules on our simulator platforms during 2023.
New endometriosis module for ScanTrainer for launch in 2023
It is estimated that 10% of women worldwide have endometriosis.
The ScanTrainer endometriosis augmented reality training module
will support clinicians in learning how to locate and identify
endometriotic disease in the ovaries, bowel and bladder using
transvaginal ultrasound. The new module is expected to launch in
May 2023.
Territory Review
Simulation revenues again grew strongly during the year, with
revenue increasing by 28% to GBP9.4m (2021: GBP7.4m). However,
there were significant variations in the performance across our
three sales regions:
United Kingdom
Revenue increased by 96% to GBP4.9m (2021: GBP2.5m)
The UK had its second consecutive record year, with NHS spending
on our simulators continuing to grow across all product lines. As
indicated in our interim report in August 2022, we had a high
number of one-off, individual orders from a UK NHS training
initiative that totalled c.GBP1.9m over the full year. Although all
our simulator sales are considered one-offs, if we exclude these
exceptional orders, the UK like-for-like revenue would have been
GBP3.0m, representing a growth of 15%. With a broad product
portfolio, there remains good scope for growth within the UK and
there continues to be strong purchasing interest in all our
simulation products.
We therefore look forward to continuing the growth of the UK
direct to market business in 2023.
North America
Revenue increased by 3% to GBP2.8m (2021: GBP2.7m)
Sales in North America grew to a record high of GBP2.8m, but
this was a disappointing performance relative to our expectations,
as a high number of capital expenditure funding freezes were
implemented by the larger teaching hospitals in the US, resulting
in cancelled or delayed purchases of our simulators in the second
half of the year. Although this loss of revenue was compensated for
by a GBP0.3m positive exchange rate variance, the like-for-like US
dollar sales during the year were down 9% to $3.4m (2021:
$3.8m).
However, North America is a key market for the Group and we have
therefore continued to invest in growing the US based sales and
marketing operation. We now have seven sales-related staff
supported by a web-based clinical applications specialist plus an
office-based support team in Alpharetta, Georgia. We believe we
will see the benefit of this investment in 2023 and beyond.
2022 witnessed the beginnings of a post Covid-19 resurgence in
major face-to-face trade exhibitions in the US and with an
encouraging start to the year and a solid pipeline of
opportunities, we look forward to a significant improvement in the
North American direct to market business in 2023.
Rest of the World
Revenue declined by 19% to GBP1.7m (2021: GBP2.1m)
2022 was a difficult year for the 23 resellers that sell our
simulators outside the UK and North America. Positive sales growth
in countries such as Japan and Germany were offset by the continued
Covid-19 restrictions in China, the loss of revenue from our
decision to stop selling in Russia, and a disappointing market in
France, that constrained our joint sales venture with Skills
Meducation, where we are in the early stages of part-funding an
Intelligent Ultrasound only sales team. Although this impacted
sales in 2022, we see a more positive outlook for China with the
Covid-19 restrictions lifting and the recruitment of a new,
experienced French sales team is expected to improve sales in
France in 2023.
With the increased range of products, a growing pipeline and
anticipated sales growth from France and China, we look forward to
a growing reseller market in 2023.
CLINICAL AI (Clinic)
Real-time clinical AI-driven software that makes ultrasound
easier to use for medical professionals remains a key part of our
'Classroom to Clinic' vision, and although we are still in the
early stages of commercialisation, clinical AI-related revenue for
the year grew over 200% to GBP0.7m (2021: GBP0.2m).
Our products provide a range of real-time support to clinicians
including real-time workflow enhancements that support faster, more
standardised scanning, but importantly also support decision
making, so that the stress of scanning is reduced and the
'burn-out' of operators being asked to increase productivity is
minimised.
We now have three AI-driven software products available in the
market:
-- ScanNav Assist obstetric AI software that is utilised by GE
HealthCare as SonoLyst on their ultrasound machines
-- ScanNav Anatomy Peripheral Nerve Block (PNB) for real-time
regional anaesthesia highlighting
-- NeedleTrainer that incorporates the PNB software to teach ultrasound-guided needling skills
Two major milestones were achieved in the year:
-- In July 2022, GE HealthCare launched the SonoLyst technology
on the Voluson Expert 22 ultrasound machine, that utilises our
ScanNav Assist AI software
-- In October 2022, ScanNav Anatomy Peripheral Nerve Block
(PNB), our second AI product, received FDA De Novo clearance for
sale in the US
We expect 2023 to be a year of significant sales growth in our
AI related sales.
ScanNav Assist
Our ScanNav Assist AI technology drives GE HealthCare's SonoLyst
X/IR software, the world's first fully integrated ultrasound AI
tool that automatically and in real-time recognises the 21 views
recommended for fetal sonography imaging.
Currently available as an optional extra on GE HealthCare's
Voluson SWIFT and Expert 22 ultrasound machines, the SonoLyst
software augments a sonographer's scanning skills, helping faster
and more standardised scanning. Acting as a virtual on-board
expert, SonoLyst automatically identifies the fetal anatomy seen on
standard views and can be used to compare the image or view
acquired to a standard criteria, ensuring exam quality and
consistency. By automatically and in real-time supporting the
sonographer in their decision making, the software also helps
reduce the often-considerable stress of obtaining the recommended
views.
The issue of burnout in scanning centres is increasing around
the world and it is hoped that the adoption of this technology will
help reduce this burden.
Our long-term agreement with GE HealthCare was signed in 2019.
GE HealthCare is the largest medical imaging company in the world,
have the exclusive rights to our clinical AI technology in the
field of women's healthcare and have now launched SonoLyst on two
of its Voluson ultrasound machine ranges. The launch in July of
SonoLyst on the Voluson Expert 22 was a key commercial milestone
for Intelligent Ultrasound, as this is GE HealthCare's premium
ultrasound machine in their women's health range.
Over 30,000 ultrasound machines are sold annually in the global
obstetrics market and GE HealthCare is the dominant manufacturer.
We therefore expect to see increased SonoLyst sales throughout 2023
and beyond as SonoLyst continues to be rolled out on the Expert 22
system.
In January 2022, we announced we had signed an extension to our
GE HealthCare agreement to enable GE HealthCare to utilise the
ScanNav Assist AI software in a new segment of automated ultrasound
image analysis, that is outside the Group's original agreement. As
with the main agreement, the terms, product sales and the timings
of the related product launches are undisclosed.
Future variants of ScanNav Assist that will support additional
protocol-based scanning are in advanced development.
ScanNav Anatomy Peripheral Nerve Block (PNB)
ScanNav Anatomy PNB simplifies ultrasound-guided needling by
providing the user with real-time AI-driven anatomy highlighting
for a range of medical procedures. The device supports the
performance of healthcare professionals who are suitably qualified,
but who perform ultrasound-guided local anaesthesia procedures on a
less frequent basis.
ScanNav Anatomy PNB achieved a major milestone in October 2022
when it was cleared by the FDA as a De Novo device for sale in the
US. The De Novo regulatory process provides a marketing pathway to
classify novel medical devices with a low to medium risk for their
intended use, where there is no existing legally marketed
comparable device.
The device supports nine common peripheral nerve blocks and is
sold as a stand-alone screen that is plugged into existing
anaesthesiology ultrasound machines to provide clinicians with
real-time highlighting of their live ultrasound. Users can also
re-familiarise themselves with blocks that are carried out less
frequently using the system's integrated 3D animations.
ScanNav Anatomy PNB is now available for sale in the UK, France,
Germany, Spain, Scandinavia and the US. With over 25,000
anaesthesiology machines in operation in these markets, and
ultrasound-guided peripheral nerve blocks increasingly being used
as a prudent alternative to general anaesthesia as well as a method
of concurrent analgesia (potentially reducing opioid usage). Our
aim is to support anaesthetists, who are competent but less
confident in the specialist knowledge of ultrasound anatomy, to
perform nerve blocks and as a result increase the number of
ultrasound-guided nerve blocks that they can perform.
A number of studies were released during the year to support the
adoption of the system and 2023 will continue this focus, as we aim
to educate and grow the market for ScanNav Anatomy PNB.
ScanNav Anatomy PNB is also available as a training simulator
for medical learning on volunteers, prior to patient contact (see
NeedleTrainer below).
NeedleTrainer
NeedleTrainer was relaunched to the market in September 2022 as
a standalone needle training device incorporating the new GE
HealthCare Vscan Air handheld ultrasound device. Developed by the
clinical AI software team as a spin-off from the ScanNav Anatomy
PNB research and development, NeedleTrainer is a portable, plug-in
system that uses a retractable needle and real-time, virtual image
overlays to simulate needling non-invasively on a live volunteer,
using the live ultrasound scan. This enables medical professionals
to develop hand-eye coordination, optimum positioning, and accuracy
in ultrasound-guided interventional procedures in a safe,
realistic, simulated-clinical environment.
The system is sold with the trainer version of our ScanNav
Anatomy PNB AI-driven software integrated into the device and is
being sold into major simulation centres, anaesthesiology
departments, emergency and primary healthcare.
Future ScanNav AI products
During 2022 the focus of the division remained on developing the
partnership with GE HealthCare, commercialising ScanNav Assist,
achieving FDA De Novo clearance for ScanNav Anatomy PNB and
relaunching NeedleTrainer with the GE HealthCare Vscan Air handheld
ultrasound system. In addition, the development team continues to
work on proof-of-concept AI software to facilitate the automatic
recognition of abnormalities within a general medical ultrasound
scan, confirming that a clinician has correctly scanned the
anatomical area of interest, and then flagging any areas of
potential abnormality, so patients can be triaged to a
specialist.
Challenges to the 'Classroom to Clinic' Business
Ultrasound continues to be a growing medical diagnostic tool,
with increasing demand for training tools that can enhance a
medical practitioner's scanning skills and clinical products that
can assist sonographers. However, there have historically always
been capital expenditure limitations on medical training budgets
for high value medical simulators and on the clinical side hospital
funding can also be hard to access, with most purchases being made
on a 6 to 18-month purchase cycle. This makes annual revenues
harder to forecast, especially during times of government spending
cutbacks, political upheaval, changes of government or pandemics
when funds can be diverted to frontline care.
The purchasing decisions made by medical institutions in the
high value sector of the simulation market remain broadly based on
the quality of training combined with value for money, rather than
simply the lowest priced solution. During 2022, we continued to
respond well to competitive products and pricing and margin
pressures by offering a variety of purchase price points, expanding
our product extensions and increasing our e-learning options that
can work in tandem with our hands-on training simulators.
To counter clinical funding constraints our clinical AI products
are competitively priced and aim to either provide improvements to
the workflow, destress the scanning process or enable more
clinicians to confidently complete a procedure that will save a
hospital money.
Although we continued to experience supply chain pressure during
the year, we were able to increase our key component stock holding
in 2022, as well as switch a number of our tracking sensors to an
alternative supplier. This enabled us to successfully avoid any
disruption to sales in the year and we believe it has also
minimised
the component supply risk for 2023. It did however increase the amount of cash tied up in stock.
Simulation product cost of goods increased by approximately 6%
during the year and as a result we had to increase the list price
of many of our products. We continue to review supplier costs and
overheads but expect the impact of price rises on our cost of goods
in 2023 to be broadly similar to 2022, which we expect will result
in a broadly similar impact on our end user pricing in the second
half of 2023.
The AI-based ultrasound imaging software market is recognised as
having significant global potential and as such there is
considerable competition from both the existing ultrasound
manufacturers and well-funded independent AI software vendors. With
the revenue models for AI-driven software still in the early stages
of commercialisation our two-pronged go-to market strategy aims to
identify the most effective route to material revenues:
-- Our ScanNav Assist software is being sold through a
royalty-based, 'on-machine' licence with GE HealthCare, whose
established sales network can provide faster roll-out of our
technology in the new ultrasound machine market; and
-- Our ScanNav Anatomy PNB software is being sold through our
own sales network directly to the global pool of existing
ultrasound machines via our own portable 'plug-in' real-time AI
enabled device.
The challenge of recruiting high calibre AI software engineers
eased in 2022 and we hope that the combination of attractive,
flexible salary packages, and a flexible work environment in a
vibrant university capital city will enable this to continue in
2023.
During 2023 we expect the restrictions caused by the pandemic to
have fully receded in all our markets, but there remains a threat
that the continued Russian invasion and occupation of Ukraine could
escalate to the point where it impacts our other European
markets.
The impact of inflation and interest rates on global healthcare
spending is also of concern.
Quality Management System
Meeting the standards of ISO 13485:2016 remains a high priority
for the Group, as we continue to ensure the consistent design,
development, production, installation, and sale of medical devices
that are safe for their intended purpose.
Workplace environment
One of the benefits of the pandemic was that it forced companies
to operate remotely and enabled staff and companies to trial
working on a more flexible basis. Once the full impact of the
pandemic ended in 2022, we took the decision to continue to operate
the company on a flexible basis, where appropriate. This has been
well received by our staff and we believe it makes a significant
contribution to the attractiveness of working for Intelligent
Ultrasound. In our 2022 annual staff survey, over 90% of staff
recommended the Group as a great place to work, with many citing
that the Company has a great ethos and is doing rewarding work that
is making a real difference to hospitals and patients around the
world.
As ever, our staff have been tremendous throughout the year, and
I would like to thank them for all their hard work in enabling us
to achieve a record year.
Shareholders
I would also like to thank our shareholders for not just
supporting the GBP5.2m placing, but also supporting our vision that
a currently small UK company can be a major player in the $1.3
billion AI related ultrasound imaging market and produce cutting
edge AI software that will make ultrasound easier to use for
medical professionals around the world.
Looking ahead
Five years ago, we embarked on our 'classroom to clinic' vision
to specialise in providing medical professionals with real-time,
hi-fidelity, augmented reality simulation for the ultrasound
training market ('the classroom') and then follow them into
clinical scanning and provide real-time, artificial
intelligence-based, clinical image analysis software tools for the
diagnostic medical ultrasound market ('the clinic').
With the important milestone of FDA De Novo clearance achieved
for our second AI-driven product and an excellent partnership with
GE HealthCare, we are well placed to turn our 'classroom to clinic'
vision into commercial reality. A positive start in Q1 2023, a
growing range of both AI and simulation related products, an
established operational base, and a successful GBP5.2m placing
increasing our cash to GBP7.2m, means we expect 2023 to be a year
of continued commercial growth, as we drive the Group to our goal
of profitability by the end of 2024.
Stuart Gall
Chief Executive Officer
FINANCIAL REVIEW
Summary financial performance:
GBPm 2022 2021 Change
(unless otherwise stated)
Revenue 10.10 7.60 +33%
------- ------- -------
Gross profit 6.33 4.66 +36%
------- ------- -------
Gross profit margin (%) 63% 61% +2%
------- ------- -------
Total R&D spend (3.20) (3.23) -1%
------- ------- -------
Administrative expenses (excluding expensed
R&D) (8.32) (7.04) +18%
------- ------- -------
Operating loss (3.67) (4.33) -15%
------- ------- -------
Loss after taxation (2.98) (3.61) -17%
------- ------- -------
Net cash used in operating activities (0.68) (1.82) -62%
------- ------- -------
Cash and cash equivalents 7.17 4.95 +45%
------- ------- -------
Income statement
Revenue
The Group delivered strong growth in 2022 with revenues up 33%
to a record high of GBP10.1m (2021: GBP7.6m) with growth in
revenues achieved across both revenue streams. We continued to
experience significant growth in the UK with revenue up 104% from
2021, however Covid-19 related challenges continued to impact
reseller markets in Asia and Europe where revenues declined by 14%
year on year.
Simulation
GBPm 2022 2021 Change
UK 4.91 2.51 +96%
----- ----- -------
North America 2.78 2.73 +3%
----- ----- -------
Rest of the World 1.74 2.15 -19%
----- ----- -------
9.43 7.39 +28%
----- ----- -------
Simulation revenue grew 28% year-on-year largely driven by
significant growth in sales in the UK which almost doubled in 2022,
due in part to a NHS ultrasound training programme to standardise
training in echocardiography across NHS England. Revenue from North
America also increased by 3% due to positive exchange rate
movements of GBP0.3m but on a like for like US dollar basis revenue
had declined by 9% to $3.4m (2021: $3.8m).
It was also another difficult year for our resellers in the Rest
of the World where sales were down 19% to GBP1.7m (2021: GBP2.15m)
due to ongoing Covid-19 restrictions in China, the decision to
prohibit sales to Russia and also a disappointing performance in
France.
Clinical AI
GBPm 2022 2021 Change
UK 0.24 0.02 0.22
----- ----- -------
North America 0.16 - 0.16
----- ----- -------
Rest of the World 0.27 0.19 0.08
----- ----- -------
0.67 0.21 0.46
----- ----- -------
Clinical AI revenues began to gain commercial traction in 2022
with revenues increasing to GBP0.67m (2021: GBP0.21m). AI royalty
revenue in 2022 and 2021 is split based on the location of the
country of invoicing rather than by end user geographical
location.
Gross profit
Group gross profit increased by 36% to GBP6.33m (2021:
GBP4.66m), the increase being higher than revenue growth due to a
higher weighting of direct versus reseller sales as well as
favourable USD exchange rate movements.
Simulation gross margin percentage went up 2% to 63% (2021: 61%)
with 82% of revenue coming from direct sales in the UK and North
America (2021: 71%) as well as favourable USD exchange rate
movements. We were also able to pass on some inflationary raw
material cost pressures where possible through sales price
increases. Some supply chain disruption continued to present
challenges during the year, but these were overcome by maintaining
adequate buffer inventories.
Clinical AI gross margin declined to 60% (2021: 74%) due to the
one-off cost of a component upgrade to the NeedleTrainer V2
demonstration units, which reduced gross margin by 14%. Excluding
this one-off cost, the Clinical AI gross margin increased to 79% on
a like-for-like basis.
Administrative expenses
GBPm 2022 2021 Change
Sales, marketing and distribution 3.08 2.44 +26%
----- ----- -------
Other general and administrative 3.48 2.86 +22%
----- ----- -------
Other non-cash costs:
----- ----- -------
Share based payment charges 0.38 0.53 -28%
----- ----- -------
Depreciation and amortisation 1.38 1.19 +16%
----- ----- -------
8.32 7.02 +18%
----- ----- -------
Administrative expenses, excluding expensed R&D costs,
increased by 18% to GBP8.32m (2021: GBP7.02m). Despite some
challenges affecting the US market in 2022, the long-term
opportunity for commercial growth exists and to address this we
have further invested in sales and marketing in this key region as
well as in our UK marketing and product management teams to be able
to maximise the potential from these growth opportunities. In
addition, a lot of the sector conferences and exhibitions, key to
sales lead generation, that were cancelled or held virtually in
2021 returned in 2022, resulting in an increase of marketing costs
of GBP0.17m (+67%) in 2022. Sales travel also returned to
pre-pandemic levels in 2022, increasing costs year on year by
GBP0.15m.
Other general and administrative costs increased by 22% due
partly to headcount increases in central functions combined with
salary increases, as well as higher general travel costs and legal
and professional costs.
Operating loss
The operating loss reduced by 15% to GBP3.67m (2021: GBP4.33m)
due to the 36% improvement in gross profit, partly offset by a 18%
increase in administrative expenses (detailed above).
Research and development (R&D) costs
GBPm 2022 2021 Change
Expensed 1.69 1.96
----- ----- -------
Capitalised 1.51 1.27
----- ----- -------
Total R&D 3.20 3.23 -1%
----- ----- -------
Simulation 1.24 1.15 +8%
----- ----- -------
Clinical AI 1.96 2.08 -6%
----- ----- -------
The Group incurred R&D expenditure of GBP3.20m (2021:
GBP3.23m). The Simulation R&D team was largely focused on
increasing the BabyWorks functionality as well as development of
the new version of BodyWorks. The Clinical AI R&D team
continued the development of the ScanNav Anatomy PNB product, in
particular in relation to progressing the product through US FDA
regulatory clearance, achieved in October 2022, as well as further
improvements to NeedleTrainer and the development of other variants
of ScanNav Assist. With significant costs of taking ScanNav Anatomy
PNB through US FDA clearance incurred in 2021, Clinical AI R&D
costs were lower in 2022.
Taxation
The total tax credit in 2022 was GBP0.72m (2021: GBP0.76m). The
Group claims each year for R&D tax credits and, since it is
loss-making, elects to surrender these tax credits for a cash
rebate.
As at 31 December 2021, the Group had cumulative gross UK tax
losses of approximately GBP19.2m (31 December 2021: GBP17.3m) for
which the Group continues to hold a cautious view, and consequently
the Group has chosen not to recognise those losses fully as a
deferred tax asset.
Balance sheet
The balance sheet was strengthened in December following a
successful share placing and subscription of a net GBP4.81m after
costs. This contributed significantly to net assets increasing to
GBP12.16m at the year end (31 December 2021: GBP9.72m).
Included within trade and other receivables of GBP2.03m (31
December 2021: GBP2.65m) are trade receivables of GBP1.36m (31
December 2021: GBP1.89m), lower than the previous year end due to
timing of invoicing and customer payments in the last quarter.
Inventory of GBP1.60m (31 December 2021: GBP1.20m) increased by
GBP0.40m due to timing of receipt of certain high value bulk stock
items as well as an adequate amount of buffer stock in the event of
any supply chain disruption.
Included within current assets is the R&D tax credit
receivable of GBP0.71m (31 December 2021: GBP0.95m). This is
GBP0.24m lower than as at 31 December 2021 due to the balance in
2021 including GBP0.2m of the 2020 receivable, which was received
at the start of 2022.
During the year GBP1.49m (2021: GBP1.27m) of product development
costs were capitalised within intangible assets with more
development costs meeting the criteria for capitalisation in 2022
compared to the prior year.
Current liabilities were to GBP3.28m (31 December 2021:
GBP3.21m), with trade payables of GBP1.36m (31 December 2021:
GBP1.35m) and accruals of GBP0.97m (31 December 2021: GBP1.23m)
largely relating to sales-based royalties payable, sales
commissions and annual bonuses. Lease liabilities of GBP0.49m (31
December 2021: GBP0.67m), relating to offices, the warehouse
facility and company cars, reduced by GBP0.18m in 2022 with ongoing
lease payments. New leases in the year related to the US office
lease renewal.
Deferred income at 31 December 2022 was GBP0.55m (31 December
2021: GBP0.53m) which relates to extended warranties and technical
support. These amounts are deferred and released to the income
statement over the life of the extended warranty and support
period.
The share based payment reserve increased by GBP0.38m to
GBP1.75m (31 December 2021: GBP1.37m) due to the share based
payment charge for the year.
Cash flow
The Group reported cash and cash equivalents of GBP7.17m at 31
December 2022 (31 December 2021: GBP4.95m).
Operating cash outflows before working capital movements of
GBP1.91m (2021: GBP2.61m) improved by GBP0.70m in 2022 due to the
higher trading levels in the year offset partly by increases in
administrative expenses. Movements in working capital of GBP0.26m
(2021: GBP0.31m) and higher R&D tax credits received in the
year of GBP0.96m (2021: GBP0.48m) resulted in the net cash used in
operating activities reducing by 62% to GBP0.68m (2021:
GBP1.82m).
The net cash outflow arising from investing activities was
GBP1.82m (2021: GBP1.78m) relating to capitalised R&D
expenditure of GBP1.47m (2021: GBP1.28m) and GBP0.36m (2021:
GBP0.50m) of property, plant and equipment, the majority of which
relates to the capitalisation of sales demonstration equipment.
The net cash inflow from financing activities was GBP4.55m
(2021: GBP0.22m outflow) as a result of the gross proceeds from the
share placing of GBP5.2m reduced by issue costs of GBP0.39m. We
also paid GBP0.23m (2021: GBP0.20m) in lease payments.
Going concern
In undertaking a going concern review, the Directors have
reviewed two financial projections to 31 December 2024 based on the
existing base budget and a flexed, more conservative version of the
base budget; both of which include estimates and assumptions
regarding the product development projects, sales pipeline, future
revenues and costs and timing and quantum of investments in the
R&D programmes. Both forecasts indicate that the Group should
be able to operate within the limits of its existing resources and
therefore the Directors have a reasonable expectation that the
Company and the Group can continue in operational existence for at
least twelve months from the date of approval of the financial
statements. Therefore, the Company and Group continues to adopt the
going concern basis in preparing its financial statements.
CONSOLIDATED STATEMENT OF PROFIT AND LOSS AND OTHER
COMPREHENSIVE INCOME
for the year ended 31 December 2022
Continuing operations Note 2022 2021
GBP'000 GBP'000
Revenue 2 10,100 7,596
----- --------- ---------
Cost of sales (3,766) (2,937)
----- --------- ---------
Gross profit 6,334 4,659
----- --------- ---------
Other income 3 8 2
----- --------- ---------
Administrative expenses (10,014) (8,993)
----- --------- ---------
Operating loss (3,672) (4,332)
----- --------- ---------
Finance income 1 1
----- --------- ---------
Finance costs (31) (37)
----- --------- ---------
Loss before taxation (3,702) (4,368)
----- --------- ---------
Taxation 4 718 758
----- --------- ---------
Loss attributable to the equity shareholders
of the Parent (2,984) (3,610)
----- --------- ---------
Other comprehensive income
----- --------- ---------
Items that may be reclassified to profit or
loss:
----- --------- ---------
Exchange gain arising on translation of foreign
operations 238 33
----- --------- ---------
Other comprehensive gain for the period 238 33
----- --------- ---------
Total comprehensive loss attributable to the
equity shareholders of the Parent (2,746) (3,577)
----- --------- ---------
Loss per ordinary share attributable to the
equity shareholders of the Parent
----- --------- ---------
Basic and diluted (pence) (1.08) (1.34)
----- --------- ---------
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
as at 31 December 2022
Note 2022 2021
GBP'000 GBP'000
Non-current assets
----- --------- ---------
Intangible assets 3,272 2,558
----- --------- ---------
Property, plant and equipment 1,174 1,400
----- --------- ---------
Trade and other receivables 61 61
----- --------- ---------
4,507 4,019
----- --------- ---------
Current assets
----- --------- ---------
Inventories 1,603 1,196
----- --------- ---------
Trade and other receivables 2,025 2,650
----- --------- ---------
Current tax assets 713 954
----- --------- ---------
Cash and cash equivalents 7,166 4,950
----- --------- ---------
11,507 9,750
----- --------- ---------
Total assets 16,014 13,769
----- --------- ---------
Current liabilities
----- --------- ---------
Trade and other payables (2,732) (2,767)
----- --------- ---------
Deferred income (337) (206)
----- --------- ---------
Lease liabilities (188) (213)
----- --------- ---------
Provisions (22) (22)
----- --------- ---------
(3,279) (3,208)
----- --------- ---------
Non-current liabilities
----- --------- ---------
Deferred income (209) (320)
----- --------- ---------
Lease liabilities (298) (457)
----- --------- ---------
Other payables (65) (65)
----- --------- ---------
(572) (842)
----- --------- ---------
Total liabilities (3,851) (4,050)
----- --------- ---------
Net assets 12,163 9,719
----- --------- ---------
Equity
----- --------- ---------
Share capital 6 3,269 2,707
----- --------- ---------
Share premium 30,207 25,959
----- --------- ---------
Accumulated losses (29,951) (26,967)
----- --------- ---------
Share-based payment reserve 1,753 1,373
----- --------- ---------
Merger reserve 6,538 6,538
----- --------- ---------
Foreign exchange reserve 182 (56)
----- --------- ---------
Other reserves 165 165
----- --------- ---------
Total equity 12,163 9,719
----- --------- ---------
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
for the year ended 31 December 2022
Share Share Share Accumulated Share-based Merger Foreign Other
capital premium warrants losses payment reserve exchange reserves Total
GBP'000 GBP'000 GBP'000 GBP'000 reserve GBP'000 reserve GBP'000 equity
GBP'000 GBP'000 GBP'000
As at 31
December 2020 2,694 25,959 126 (23,381) 842 6,538 (89) - 12,689
-------- -------- --------- ------------ ------------ --------- --------- --------- ---------
Loss for the
year - - - (3,610) - - - - (3,610)
-------- -------- --------- ------------ ------------ --------- --------- --------- ---------
Other
comprehensive
loss - - - - - - 33 - 33
-------- -------- --------- ------------ ------------ --------- --------- --------- ---------
Total
comprehensive
loss for the
year - - - (3,610) - - 33 - (3,577)
-------- -------- --------- ------------ ------------ --------- --------- --------- ---------
Transactions with owners, recorded directly in equity
Issue of share
capital 13 - - - - - - 13
-------- -------- --------- ------------ ------------ --------- --------- --------- ---------
Exercise of
share
warrants - - (126) 24 - - - 165 63
-------- -------- --------- ------------ ------------ --------- --------- --------- ---------
Cost of
share-based
awards - - - - 531 - - - 531
-------- -------- --------- ------------ ------------ --------- --------- --------- ---------
As at 31
December 2021 2,707 25,959 - (26,967) 1,373 6,538 (56) 165 9,719
-------- -------- --------- ------------ ------------ --------- --------- --------- ---------
Loss for the
year - - - (2,984) - - - - (2,984)
-------- -------- --------- ------------ ------------ --------- --------- --------- ---------
Other
comprehensive
income - - - - - - 238 - 238
-------- -------- --------- ------------ ------------ --------- --------- --------- ---------
Total
comprehensive
loss for the
year - - - (2,984) - - 238 - (2,746)
-------- -------- --------- ------------ ------------ --------- --------- --------- ---------
Transactions with owners, recorded directly in equity
Issue of share
capital 562 4,248 - - - - - - 4,810
-------- -------- --------- ------------ ------------ --------- --------- --------- ---------
Cost of
share-based
awards - - - - 380 380
-------- -------- --------- ------------ ------------ --------- --------- --------- ---------
As at 31
December 2022 3,269 30,207 - (29,951) 1,753 6,538 182 165 12,163
-------- -------- --------- ------------ ------------ --------- --------- --------- ---------
CONSOLIDATED STATEMENT OF CASH FLOWS
for the year ended 31 December 2022
2022 2021
GBP'000 GBP'000
Cash flows from operating activities
--------- ---------
Loss before taxation (3,702) (4,368)
--------- ---------
Depreciation 604 508
--------- ---------
Amortisation of intangible assets 780 680
--------- ---------
Fair value adjustment to share warrants - 3
--------- ---------
Net finance costs 30 36
--------- ---------
Share-based payment charge 380 530
--------- ---------
Operating cash flows before movement in working
capital (1,908) (2,611)
--------- ---------
Movement in inventories (404) (149)
--------- ---------
Movement in trade and other receivables 739 (592)
--------- ---------
Movement in trade and other payables (70) 1,045
--------- ---------
Movement in provisions - 12
--------- ---------
Cash used in operations (1,643) (2,295)
--------- ---------
Income taxes received 959 476
--------- ---------
Net cash used in operating activities (684) (1,819)
--------- ---------
Cash flows from investing activities
--------- ---------
Purchase of property, plant and equipment (357) (503)
--------- ---------
Internally generated intangible assets (1,467) (1,275)
--------- ---------
Interest received 1 1
--------- ---------
Net cash (used in) investing activities (1,823) (1,777)
--------- ---------
Cash flows from financing activities
--------- ---------
Proceeds from issue of new shares 5,200 13
--------- ---------
Share issue costs (390) -
--------- ---------
Principal elements of lease payments (231) (195)
--------- ---------
Interest paid (31) (37)
--------- ---------
Net cash generated by/(used in) financing activities 4,548 (219)
--------- ---------
Net increase/(decrease) in cash and cash equivalents 2,041 (3,815)
--------- ---------
Cash and cash equivalents at beginning of year 4,950 8,774
--------- ---------
Exchange losses on cash and cash equivalents 175 (9)
--------- ---------
Cash and cash equivalents at end of year 7,166 4,950
--------- ---------
1. GENERAL INFORMATION
Intelligent Ultrasound Group plc ("the Company") is a publicly
limited liability company incorporated and domiciled in the United
Kingdom whose shares are traded on AIM, a market operated by the
London Stock Exchange. The Company's registration number is
09028611 and its registered office address is Floor 6A Hodge House,
114-116 St Mary Street, Cardiff, CF10 1DY.
These results do not constitute the Group's statutory accounts
for the year ended 31 December 2022 but are derived from those
accounts. Statutory accounts for 2021 have been delivered to
Companies House and those for 2022 will be delivered following the
Company's Annual General Meeting. The external auditors have
reported on those accounts; its report was unqualified and did not
contain any statements under section 498 of the Companies Act
2006.
Going concern
In undertaking a going concern review, the Directors have
reviewed two financial projections to 31 December 2024 based on the
existing base budget and a flexed, more conservative version of the
base budget; both of which include estimates and assumptions
regarding the product development projects, sales pipeline, future
revenues and costs and timing and quantum of investments in the
R&D programmes. Both forecasts indicate that the Group should
be able to operate within the limits of its existing resources and
therefore the Directors have a reasonable expectation that the
Company and the Group can continue in operational existence for at
least twelve months from the date of approval of the financial
statements. Therefore, the Company and Group continues to adopt the
going concern basis in preparing its financial statements.
The Directors continue to explore additional sources of income
and finance available to the Group to continue the development of
its 'classroom to clinic' business.
Impairment assessment of Clinical AI intangible assets
For the intangible assets that have a finite life, the Directors
considered the need to impair the carrying value of intangible
assets by performing a review for indicators of impairment by
assessing the performance of the assets against qualitative and
quantitative factors. If any of these factors are present a
detailed impairment review is undertaken. A detailed impairment
assessment is performed by assessing the assets value in use which
requires management to make a number of estimates. The most
sensitive estimate is in relation to management's estimates of
future revenues on the basis that these are new products which have
no extensive history of sales upon which to base the forecasts.
During the period ended 31 December 2022, the Clinical AI
related assets of GBP1.5m were tested for impairment.
The calculations use five-year cash flow projections based on
financial budgets approved by management covering a two-year
period. Cash flows for periods three to five are extrapolated using
estimated growth rates and growth rates beyond five years are
consistent with forecasts specific to the sector in which the CGU
operates.
Reasonable sensitivities applied to the cashflow projections
indicate that there is significant headroom before any impairment
would be required. A 69% reduction in the budgeted revenue used in
the value-in-use calculation for the IUL acquired intangible assets
would result in full impairment of the carrying value of the asset
by GBP1.5m.
2. OPERATING SEGMENTS
Operating segments reflect the way in which information is
presented to and reviewed by the CODM for the purposes of making
strategic decisions and assessing Group-wide performance. The
Group's Board of Directors ('the Board') is the Group's CODM. The
Group evaluates performance of the operational segments on the
basis of revenue and gross profit. Apart from Intangible assets and
Property plant & equipment, all other assets and liabilities
are reported to the Board at Group level and are not separated
segmentally.
The format of revenue reporting is based on the Group's
management and internal reporting (including reports to the CODM).
The Group has two operating segments: Simulation and Clinical
AI.
-- Simulation: sales of ultrasound simulation systems and related services
-- Clinical AI: sales of AI-related ultrasound image analysis software products
2022 Simulation Clinical Total
GBP'000 AI GBP'000
GBP'000
Revenue 9,432 668 10,100
----------- --------- ---------
Cost of sales (3,502) (264) (3,766)
----------- --------- ---------
Gross profit 5,930 404 6,334
----------- --------- ---------
2021 Simulation Clinical Total
GBP'000 AI GBP'000
GBP'000
Revenue 7,390 206 7,596
----------- --------- ---------
Cost of sales (2,883) (54) (2,937)
----------- --------- ---------
Gross profit 4,507 152 4,659
----------- --------- ---------
Revenue by destination of external customer
2022 2021
GBP'000 GBP'000
United Kingdom 5,145 2,553
--------- ---------
North America (USA & Canada) 2,943 2,733
--------- ---------
Rest of the World 2,012 2,310
--------- ---------
10,100 7,596
--------- ---------
Timing of revenue recognition:
--------- ---------
At a point in time 9,591 7,284
--------- ---------
Over time 509 312
--------- ---------
Clinical AI royalty income is included within Rest of the World
based on the external customer's invoicing country rather than the
destination of the end customer.
Included within non-UK revenues are sales to the following
country which accounted for more than 10% of the Group's total
revenue for the year:
2022 2021
GBP'000 GBP'000
USA 2,808 2,426
--------- ---------
The Group had no customers who accounted for more than 10% of
the Group revenue for the year ended 31 December 2022 or 2021.
Other segment information
Depreciation Additions to
and amortisation non-current
assets
2022 2021 2022 2021
GBP'000 GBP'000 GBP'000 GBP'000
--------- --------- --------- ---------
Simulation 942 843 1,258 1,334
--------- --------- --------- ---------
Clinical AI 299 202 605 535
--------- --------- --------- ---------
Central 143 143 - -
--------- --------- --------- ---------
1,384 1,188 1,863 1,869
--------- --------- --------- ---------
Non-current assets based outside the UK
Right-of-use assets include leased offices for Intelligent
Ultrasound North America Inc (IUNA), based in Georgia. The net book
value as of 31 December 2022 was GBP0.03m (2021: GBP0.07m).
3. OTHER INCOME
2022 2021
GBP'000 GBP'000
UK grant income 8 2
--------- ---------
4. TAXATION
2022 2021
GBP'000 GBP'000
Current tax
--------- ---------
R&D tax credit (711) (769)
--------- ---------
R&D tax credit relating to prior periods (7) 11
--------- ---------
(718) (758)
--------- ---------
Deferred tax
--------- ---------
Origination and reversal of timing differences - -
--------- ---------
Effect of tax rate change on opening balance - -
--------- ---------
- -
--------- ---------
Income tax credit (718) (758)
--------- ---------
5. LOSS PER ORDINARY SHARE
The loss per Ordinary share has been calculated using the loss
for the year and the weighted average number of Ordinary shares in
issue during the year as follows:
2022 2021
GBP'000 GBP'000
Loss after taxation (2,984) (3,610)
--------- ---------
Number of Ordinary shares of 1p each 2022 2021
No. No.
Basic and diluted weighted average number of Ordinary
shares 275,274,014 269,964,886
--------------- ------------
Basic and diluted loss pence per share (1.08) (1.34)
--------------- ------------
At 31 December 2022 and 2021 there were share options
outstanding which could potentially have a dilutive impact but were
anti-dilutive in both years.
6. SHARE CAPITAL
Authorised, allotted, 2022 2021
issued and fully paid
Number GBP'000 Number GBP'000
------------ -------- ------------ --------
Ordinary shares of 1p
each
------------ -------- ------------ --------
Balance at 1 January 270,653,485 2,707 269,396,792 2,694
------------ -------- ------------ --------
Shares issued for cash 56,216,436 562 1,256,693 13
------------ -------- ------------ --------
At 31 December 326,869,921 3,269 270,653,485 2,707
------------ -------- ------------ --------
The nominal values and the premium arising on shares issued in
2022 and 2021 are as follows:
Date Number Nominal Premium
of shares value GBP'000
GBP'000
19 July 2021 1,256,693 13 -
----------- --------- ---------
1 and 2 December 2022 56,216,436 562 4,638
----------- --------- ---------
On 1 December 2022 the Company placed 56,216,436 newly issued
shares of 1 pence each in the capital of the Company at a price of
9.25 pence per share. Share issue costs of GBP0.39m have been
netted off against share premium arising on the new share
issue.
On 7 July 2021 pursuant to a receipt of notice for the exercise
of warrants, the Company issued 1,256,693 new Ordinary shares with
a nominal value of GBP0.01 each at a subscription price of GBP0.01
per Ordinary share. The Company has received gross proceeds of
GBP12,566.93.
Ordinary shares have a par value of 1 pence. They entitle the
holder to participate in dividends, and to share in the proceeds of
winding up the company in proportion to the number of and amounts
paid on the shares held. On a show of hands, every holder of
ordinary shares present at a meeting, in person or by proxy, is
entitled to one vote; and, on a poll, each share is entitled to one
vote. Ordinary shares have equal rights, preferences and no
restrictions on distributions of dividends nor the repayment of
capital.
The Company does not have a limited amount of authorised
capital.
7. PUBLICATION OF ANNUAL REPORT
It is anticipated that the full Annual Report will be published
in May 2022. Copies will be available at the Company's head office;
Floor 6A Hodge House, 114-116 St Mary Street, Cardiff, CF10 1DY and
on the Company website ( www.intelligentultrasound.com ).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
FR SFUFMUEDSELL
(END) Dow Jones Newswires
April 20, 2023 02:00 ET (06:00 GMT)
Intelligent Ultrasound (LSE:MED)
Historical Stock Chart
From Dec 2024 to Jan 2025
Intelligent Ultrasound (LSE:MED)
Historical Stock Chart
From Jan 2024 to Jan 2025
